Georgios Kyriakos, Lourdes V. Quiles-Sanchez, Anna Garmpi, Paraskevi Farmaki*, Konstantina Kyre, Spyridon Gkogkos, Spyridon Savvanis and Eleni Memi Pages 253 - 257 ( 5 )
Background: To report the cardiovascular and renal effects of incretin-based therapies.Methods: The studies of clinical trials on incretin-based therapy published in medical journals from the years 2010 to 2017 were comprehensively searched using MEDLINE and EMBASE with no language restriction. The studies were reviewed and the cardiovascular and renal risks reported were recorded. Results: Incretin-based therapeutics represent novel and promising anti-diabetes drugs, the direct cardiovascular actions which may translate into demonstrable clinical benefits on cardiovascular outcomes. Furthermore, incretin-based therapies do not adversely affect renal function.
Incretin-based therapies, hormones, diabetes, cardiovascular, renal, clinical trials.
Seccion de Endocrinologia y Nutrition, Hospital General Universitario Santa Lucia, Cartagena, Centro de Salud Jesús Marín, Murcia, Department of Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athen, Athens, 1st Department of Pediatrics, “Aghia Sophia Children’s Hospital” Medical School, National and Kapodistrian University of Athens, Athens, Department of Internal Medicine, KAT General Hospital, Athens, Department of Surgery, Health Center of Peristeri, Athens, Department of Internal Medicine, General Hospital of Athens "Elpis", Athens, Unit of Endocrinology, Diabetes Mellitus and Metabolism, Aretaieion University Hospital, Medical School of Athens, Ethnikon and Kapodistrian University of Athens, Athens